Tokai Pharmaceuticals Inc (NASDAQ:TKAI) has had a tough couple of months. The company collapsed towards the end of July on the news that it was discontinuing a pivotal in its lead indication. The drug under investigation was the only real asset in its pipeline, at least the only of any note, and markets are struggling […]
Author: Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.
StemCells Inc (NASDAQ:STEM): This One 8K Extract Is The Only Thing That Matters
At the end of May 2016, StemCells Inc (NASDAQ:STEM) announced it was winding down and going out of business. Fast forward three months to the third week August, and the company announced a pivot that will see it merge with a private Israeli biotech called Microbot Medical Ltd. The announcement sent the company’s share price […]
Sedor’s Record Suggests Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Is About To Be Bought Out
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) is attracting lot of attention at the moment on the back of its potential buyout. Rumors are spreading that the company is set to report that it is trying to sell itself, or even that it already has, and this is drawing speculative buy volume. If there is credence to […]